Rasche T, Emmert D, Stieber C, Conrad R, Mücke M
Zentrum für Seltene Erkrankungen (ZSEB), Universitätsklinikum Bonn, 53127, Bonn, Deutschland.
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Bonn, Bonn, Deutschland.
Internist (Berl). 2019 Mar;60(3):309-314. doi: 10.1007/s00108-019-0556-0.
Cannabis products are being increasingly liberalized all over the world and there is a huge interest in cannabis-based medicine.
Presentation of current studies on the efficacy of different cannabis-based medicine for the treatment of various diseases CURRENT DATA: In German pharmaceutical legislation, nabiximols is approved for the treatment of moderate to severe therapy-resistant spasticity in multiple sclerosis and nabilone is approved for the treatment of therapy-resistant chemotherapy-associated nausea and vomiting. In case of therapy failure cannabinoids, as part of an individual therapeutic attempt, may be considered for the treatment of chronic pain (neuropathic pain, cancer pain, non-neuropathic noncancer pain), cachexia in human immunodeficiency virus as well as for Dravet and Lennox-Gastaut syndrome. From the authors' perspective there is not enough evidence for the use in chemotherapy-associated nausea and vomiting and chronic non-neuropathic pain.
Currently, a wide use of cannabinoids does not seem probable in the near future. Further studies involving more patients and evaluating long-term effects are necessary.
大麻产品在全球范围内正日益自由化，人们对大麻类药物有着浓厚兴趣。
介绍目前关于不同大麻类药物治疗各种疾病疗效的研究
在德国药品立法中，纳布西莫尔被批准用于治疗多发性硬化症中至重度治疗抵抗性痉挛，那必隆被批准用于治疗治疗抵抗性化疗相关恶心和呕吐。在治疗失败的情况下，作为个体化治疗尝试的一部分，大麻素可考虑用于治疗慢性疼痛（神经性疼痛、癌痛、非神经性非癌性疼痛）、人类免疫缺陷病毒相关恶病质以及德雷维特综合征和伦诺克斯 - 加斯东综合征。从作者的角度来看，在化疗相关恶心和呕吐以及慢性非神经性疼痛的使用方面没有足够的证据。
目前，在不久的将来大麻素似乎不太可能广泛使用。有必要进行更多涉及更多患者并评估长期效果的进一步研究。
